mianserin hydrochloride / Generic mfg. - LARVOL DELTA

Validation in Drosophila of the in silico predicted clomipramine as repurposable for SOD1-ALS. (PubMed, Neurotherapeutics) - "Current Food and Drug Administration-approved drugs -riluzole, edaravone, and tofersen - offer limited clinical benefit due to ALS multifactorial etiology and high heterogeneity...Leveraging the SAveRUNNER algorithm, we identified several potentially repurposable candidates, including clomipramine (Anafranil®), mianserin (Lantanon®/Tolvon®), and modafinil (Provigil®)...Our results demonstrate that clomipramine is the most promising candidate, ameliorating lifespan reduction, improving climbing abilities, and mitigating both genomic instability and inflammation, key pathological hallmarks of these SOD1-ALS models. Despite needing further validation in higher organisms, our Drosophila findings represent preliminary yet significant support for clomipramine's action as an add-on treatment for SOD1-ALS."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Respiratory Diseases

From REM Sleep behavior disorder to Parkinson's Disease: a case report tracing the evolution from parasomnia to neurodegeneration (ECNP 2025) - "Initial pharmacological management with mianserin was ineffective, whereas clonazepam provided partial symptom relief—consistent with its known efficacy in managing RBD symptoms. Its identification, particularly in older adults, should prompt clinicians to monitor for early signs of neurodegeneration and consider referral to neurology for ongoing assessment. Early diagnosis of Parkinson's disease offers potential benefits in terms of treatment planning, patient counseling, and inclusion in neuroprotective trials."

Case report • Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Mental Retardation • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

Redressing long-term antidepressant use in general practice (RELEASE) (ECNP 2025) - "Antidepressants include selective serotonin reuptake inhibitors (sertraline, escitalopram fluoxetine, paroxetine, fluvoxamine and citalopram); serotonin and norepinephrine reuptake inhibitors (venlafaxine, desvenlafaxine, duloxetine); and other antidepressants (mirtazapine, vortioxetine, mianserin, moclobemide, reboxetine, agomelatine). 26 practices and 485 participants randomised. Data collection complete November 2025. Implications: This study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of the RELEASE multi-strategy intervention in prompting review of antidepressant medication and supporting informed decision-making and safe cessation via hyperbolic tapering to minimise withdrawal symptoms to improve primary mental health care and outcomes for patients."

Alzheimer's Disease • CNS Disorders • Dementia • Mood Disorders • Neuralgia • Psychiatry

Response probability to single intravenous racemic ketamine with psychopharmacological combinations: a pooled post-hoc study (ECNP 2025) - "The combination of ketamine with antidepressants that block 5-HT2A receptors (such as mirtazapine, mianserine, trazodone, and agomelatine; n = 41) significantly increased the response rate to 58.5%, compared to 28.9% in those who did not receive these combinations. In contrast, combining ketamine with serotonin reuptake inhibitors (escitalopram, fluoxetine, paroxetine, sertraline, vortioxetine; n = 34) or with antipsychotics characterized by higher D2 than 5-HT2A blockade (amisulpride, aripiprazole, cariprazine; n = 10) significantly reduced the response rate to 26.5% and 0%, respectively, compared to 53.8% and 48.7% in those not receiving these combinations. Combination of ketamine with serotonin and norepinephrine reuptake inhibitors (clomipramine, venlafaxine, duloxetine, milnacipran; n = 30) or with antipsychotics (n = 40), compared to ketamine without SNRIs or without antipsychotics, did not significantly alter the probability of response (p = 0.369 and p = 0.083,..."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic. (PubMed, PLoS One) - "The COVID-19 pandemic did not contribute to change in consumption of psychotropic drugs in Serbia. Still, the use of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoids increased from 2006 to 2021."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Infectious Disease • Mental Retardation • Novel Coronavirus Disease • Psychiatry

Berberine-Induced Behavioral Effects on Tail Suspension Test, BDNF, and CREB Levels in the Prefrontal Cortex, Hippocampus, and Amygdala: Modulation by Central Serotonergic Transmission. (PubMed, Synapse) - "Preinjection with the 5-HT precursor, 5-hydroxytryptophan (5-HTP; 50 and 100 µg/mouse, intracerebroventricular [i.c.v.]), and the selective serotonin reuptake inhibitor (SSRI), fluoxetine (5 and 10 mg/kg, i.p.), enhanced the berberine-induced antidepressant-like effect, whereas it was reversed in mice pretreated with 5-HT1A receptor agonist, 8-hydroxy-2(-dipropylamino)tetralinhydrobromide (8-OH-DPAT) (0.01 and 0.1 µg/mouse, i.c.v.), or the 5-HT2A/2C receptor antagonist, mianserin (1, 1.5 µg/mouse, i.c.v.). These findings suggest that serotonergic transmission modulates the antidepressant-like activity and the BDNF/CREB alterations induced by berberine, likely through a mechanism mediated by 5-HT1A and 5-HT2A/2C receptors. This study underscores the role of serotonergic transmission in the effects induced by berberine."

Journal • BDNF

Evaluation of various internal standards for quantification of dextromethorphan and diphenhydramine in plasma: a fatal overdose case of a mid-teenager caused by personally imported and over-the-counter medicines. (PubMed, Forensic Toxicol) - "The concentrations of both drugs in plasma samples were estimated to cause death. When using an alternative IS, a validation study is needed to select the optimal IS."

Journal

Environmental Antidepressants Disrupt Metabolic Pathways in Spirostomum ambiguum and Daphnia magna: Insights from LC-MS-Based Metabolomics. (PubMed, Molecules) - "Pharmaceuticals such as fluoxetine, paroxetine, sertraline, and mianserin occur in aquatic environments at low yet persistent concentrations due to their incomplete removal in wastewater treatment plants. They also underscore the considerable potential of metabolomics as a powerful and sensitive tool for ecotoxicological risk assessments, particularly when applied across multiple model organisms to capture interspecies variations. However, further research is essential to identify which specific pathway disruptions are most predictive of adverse effects on organismal health."

Journal • Metabolic Disorders

Enhanced inhibitory effects of mianserin in combination with sorafenib on liver cancer growth through targeting the CCR9-AKT pathway. (PubMed, Am J Cancer Res) - "This study is the first to demonstrated that mianserin effectively limits the growth of liver cancer by downregulating CCR9, in turn, inactivating the AKT-(β-catenin/NFκB) pathway. Both in vitro and in vivo experiments highlight mianserin's potential as an adjuvant therapy to sorafenib, offering a promising strategy to overcome current challenges in liver cancer treatment."

Journal • Liver Cancer • Oncology • Solid Tumor • HSPD1

Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation. (PubMed, Neurology) - "Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials."

Journal • Observational data • CNS Disorders • Cough • Erectile Dysfunction • Infectious Disease • Movement Disorders • Ophthalmology • Pain • Parkinson's Disease • Respiratory Diseases

Antidepressant Therapy and Depression Disorder. (PubMed, Pril (Makedon Akad Nauk Umet Odd Med Nauki)) - "Research highlights the importance of combining selective serotonin reuptake inhibitors (SSRIs) with antidepressants that act as antagonists of presynaptic α2-autoreceptors and α2-heteroreceptors, such as Mianserin, Trazodone, and Mirtazapine. Aim: to evaluate the effectiveness of combined therapy using Mirtazapine (α2-autoreceptor antagonist) and Sertraline (serotonin reuptake inhibitor) in treating depression...Additionally, the difference in HRS scores between one-month and three-month treatment periods was also significant (Z = -4.717, P ≤ 0.001). The results of our study demonstrate that initiating combined antidepressant therapy at the outset of treatment is highly effective."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sexual Disorders

An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression. (PubMed, Pharmaceuticals (Basel)) - "Comparisons with imipramine, clomipramine, amitriptyline, dothiepin, paroxetine, fluoxetine, citalopram, mianserin, nortriptyline, and moclobemide generally revealed no significant differences in efficacy. However, some reviews indicated that venlafaxine and mirtazapine were superior to fluvoxamine in certain outcomes, while fluvoxamine demonstrated greater efficacy than desipramine in one review. Sertraline and milnacipran showed mixed or review-quality-dependent results, with one low-quality review favoring milnacipran...While no single antidepressant was universally superior, fluvoxamine's unique pharmacological profile and favourable safety characteristics support its clinical utility. Further research is needed to explore its role in personalized treatment strategies and emerging therapeutic contexts, such as comorbid anxiety and post-traumatic stress disorder."

Journal • Review • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Electroconvulsive Therapy and the Onset of Diabetes: A Rare but Critical Complication in Children (ESPE-ESE 2025) - "Case Presentation A 13-year-old boy with early-onset psychosis and treatment-resistant ADHD had been on medication, including fluoxetine, olanzapine, quetiapine, and mianserin for the past two months. Conclusion Considering the uncertainty surrounding the etiology of childhood psychiatric disorders and the potential impact of ECT on glycemic control,the effect of ECT on beta cell reserve in children should be further evaluated. A multidisciplinary approach is essential during the ECT treatment process in children, with careful attention to hyperglycemic complications and more frequent monitoring of blood glucose levels."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Diabetes • Infectious Disease • Measles • Mental Retardation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Pediatrics • Psychiatry

Treatment with antidepressant drugs and hyponatremia: a network meta-analysis. (PubMed, J Endocrinol Invest) - "These data appear useful on clinical grounds, in order to increase the awareness regarding the possibility that antidepressants induce hyponatremia and to encourage regular serum sodium monitoring."

Journal • Retrospective data • Review • Cardiovascular • Heart Failure

Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis. (PubMed, Br J Psychiatry) - "Antidepressants are effective in individuals with comorbid physical conditions, although tolerability is a relevant concern. Selective serotonin reuptake inhibitors (SSRIs) have the best benefit-risk profile, making them suitable as first-line treatments, while tricyclics are highly effective but less tolerated than SSRIs and placebo."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of 23 antidepressants and active metabolites in human serum and its application in therapeutic drug monitoring. (PubMed, Front Pharmacol) - "In this paper, we developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to study simultaneously TDM and clinical pharmacokinetics of 23 antidepressants and active metabolites: sertraline, escitalopram, fluvoxamine, paroxetine, duloxetine, milnacipran, fluoxetine, venlafaxine, O-desmethylvenlafaxine, mirtazapine, trazodone, bupropion, hydroxybupropione, norfluoxetine, vortioxetine, agomelatine, mianserin, doxepine, desmethyldoxepin, clomipramine, desmethylclomipramine, amitriptyline and nortriptyline hydrochloride...Validation of the developed method was carried out based on the Chinese Pharmacopoeia guidelines for bioanalytical method validation, including assessment of specificity, calibration curves, carryover, accuracy, crosstalk, precision, stability, recovery, dilution integrity and matrix effect. The results showed that a simple, fast, reliable and specific HPLC'MS/MS method was developed and validated, and all the..."

Journal • CNS Disorders • Depression • Psychiatry

Association Between CYP2D6 Genotypes and Serum Concentrations of Mirtazapine and Mianserin. (PubMed, Basic Clin Pharmacol Toxicol) - "In conclusion, CYP2D6 genotype was only associated with a minor change in mirtazapine serum concentration. The association between CYP2D6 genotype and mianserin serum concentration was greater, with 80% higher mianserin C/D ratio in CYP2D6 PMs compared with NMs."

Journal • Retrospective data

A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? (PubMed, Pharmaceuticals (Basel)) - " The antidepressants mianserin and mirtazapine (separately) induced dose-dependent antinociception, each yielding a biphasic dose-response curve. Similarly, the antidepressant venlafaxine produced a potent effect and reboxetine produced a weak effect. The antipsychotics risperidone and amisulpride exhibited a dose-dependent antinociceptive effect... Clinical studies are mandatory to establish the potential efficacy of augmentation of the treatment with antidepressants with these drugs in persons with treatment-resistant depression and the optimal dosage of medications prescribed. We suggest a possible beneficial effect of antidepressants with kappa antagonistic properties."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics. (PubMed, Eur J Drug Metab Pharmacokinet) - "The interaction between fluvoxamine and caffeine resulted in increased concentrations of caffeine in the body and lowered the renal clearance of fluvoxamine. Other SSRIs such as fluoxetine and escitalopram had augmented antidepressant effects by decreasing their renal clearance and prolonging their effects in the body when coadministered with caffeine. Caffeine may also increase the concentration of paroxetine, potentially affecting its pharmacodynamic effects. TCAs such as clomipramine, imipramine, desipramine, and sertraline, were found to reduce the metabolism of caffeine...The inhibition of caffeine at high doses when used with MAOIs such as tranylcypromine and phenelzine was found to lead to a higher likelihood of experiencing hypertension. Coadministration of caffeine with venlafaxine (SNRIs) suggests minimal interactions between the two substances and the pharmacodynamic effects of venlafaxine were unlikely to be impacted by caffeine consumption. Miscellaneous..."

Journal • PK/PD data • Review • Cardiovascular • CNS Disorders • Hypertension • Psychiatry

Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. (PubMed, Front Pharmacol) - "Preparations containing 18% or more tetrahydrocannabinol (THC), presented significant side effects with the following antidepressants: mianserine (restless legs syndrome, urogenital pain, ventricular tachycardia), mirtazapine (pancreatitis, hyperhidrosis, arthralgia), quetiapine (myocarditis, renal failure, bradycardia, sialorrhea), haloperidol (ventricular arrhythmia, prolonged QTc), aripiprazole (prolonged QTc), ventricular tachycardia) and cariprazine (stomach pain, hepatotoxicity), sertraline (ataxia, hyperactivity, coma, hallucinations, anxiety, agitation, tachycardia, panic attacks, disorientation, headache, dizziness, blurry vision, severe emesis, xerostomia, dry eyes), trazodone (disorientation, memory impairment, sedation), fluvoxamine (tachycardia, tachypnoea, dysarthria, auditory hallucinations). Clinicians need to closely monitor adverse events resulting from the combined use of cannabinoids and psychotropic medications. The accumulation of side effects and..."

Adverse events • Journal • Retrospective data • Review • Alzheimer's Disease • Anesthesia • Ataxia • Cardiovascular • CNS Disorders • Dental Disorders • Dermatology • Dry Eye Disease • Fatigue • Hepatology • Inflammation • Mood Disorders • Movement Disorders • Musculoskeletal Pain • Ophthalmology • Pain • Pancreatitis • Psychiatry • Renal Disease • Restless Legs Syndrome • Sleep Disorder • Ventricular Tachycardia • Xerostomia

Imagery rehearsal therapy and mianserin for trauma-affected refugees: Follow-up of a randomized controlled trial. (PubMed, Torture) - "This follow-up study found improvements from baseline to post-treatment on sleep quality and most of the secondary outcome measures that were maintained for all treatment condi-tions at the six-month follow-up assessment. A limitation of the study was that a high proportion (53.4%) of the participants did not attend the follow-up evaluation. The results indicate that add-on IRT-treatment and add-on mianserin-treatment were not superior to TAU at six-month follow-up post-treatment."

Clinical • Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Effect of serotonin antagonists on sodium pump activity in rat cerebral cortex (Neuroscience 2024) - "On the other hand, Inpreliminary studies it has been observed that 5-HT2 receptor antagonists have aninhibitory effect on the activity of the enzyme, although this effect has not beencompletely characterized, so in the present work the effect of 5-HT2 receptorantagonists ( Mianserin, Ritanserine, Spiperone, Ketanserin and Cyproheptadine)on sodium pump activity was studied in cerebral cortex homogenate, in glial andneuronal membranes of the cerebral cortex of adult male rats. The results showthat there is an inhibitory effect on the activity of the enzyme in a dose-dependentmanner, as similar as an inverse agonism phenomena and possibly through the 5-HT2C receptor activation. The present results support the functional relationshipbetween neurons and glial cells as an example of cellular communication."

Preclinical • CNS Disorders

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants. (PubMed, Neuropsychopharmacology) - "Furthermore, imipramine and mianserin, two representative compounds, also demonstrated rescue of nine VMAT2 variants that cause Brain Monoamine Vesicular Transport Disease (BMVTD). VMAT2 upregulation could be beneficial for disorders associated with reduced monoamine transmission, including mood disorders and BMVTD, a rare but often fatal condition caused by a lack of functional VMAT2. Our findings provide the first evidence that small molecules can upregulate VMAT2 and have potential therapeutic benefit for various neuropsychiatric conditions."

Journal • CNS Disorders • Mood Disorders • Psychiatry

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Zhenghui YI | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Combination therapy • Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sleep Disorder

Vortioxetine-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report. (PubMed, Neuropsychopharmacol Rep) - "This is the first case report of vortioxetine-induced SIADH."

Clinical • Journal • P4 data • Retrospective data • Review • Cardiovascular • CNS Disorders • Depression • Epilepsy • Heart Failure • Major Depressive Disorder • Mood Disorders • Pain • Psychiatry